Biotechnology Company
Appears in 1 story
Full Phase 3 RASolute 302 data presented at ASCO plenary on May 31, 2026 and published simultaneously in NEJM; confirmed 33.2% ORR versus 11.8% for chemotherapy; NDA preparation underway under Commissioner's National Priority Voucher program with analysts forecasting possible Q3 2026 U.S. launch; daraxonrasib confirmed as combination partner after Tango Therapeutics reported 92% ORR with vopimetostat plus daraxonrasib in MTAP-deleted patients on June 8, 2026
On May 31, Revolution Medicines presented the full Phase 3 RASolute 302 dataset at the ASCO plenary in Chicago, simultaneously published in the New England Journal of Medicine. Daraxonrasib cut the risk of death by 60%. The drug produced a 33.2% objective response rate versus 11.8% on chemotherapy and nearly halved the rate at which patients' pain worsened.
Updated Jun 8
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
